Related Experiment Video
Updated: Jun 10, 2025
13:56
A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
Published on: July 18, 2013
11.2K
Targeting Human Papillomavirus 33 E2 DNA Binding Domain With Polyphenols: Unveiling Interactions Through Biophysical
1Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, India.
Journal of Molecular Recognition : JMR
|October 13, 2024
Summary
Resveratrol and baicalein show promise as antiviral drugs by interacting with the human papillomavirus (HPV) 33 E2 DNA binding domain (DBD). These natural compounds stabilize the protein and may inhibit viral replication.
Area of Science:
- Virology
- Biochemistry
- Drug Discovery
Background:
- Human papillomavirus (HPV) 33 is a high-risk oncogenic strain.
- The E2 protein's DNA binding domain (DBD) is vital for viral life cycle regulation and a potential therapeutic target.
Purpose of the Study:
- To investigate the interaction of resveratrol and baicalein with the HPV 33 E2 DBD.
- To assess the potential of these polyphenols as antiviral agents.
Main Methods:
- Biophysical techniques: fluorescence spectroscopy, circular dichroism, differential scanning calorimetry, isothermal titration calorimetry.
- In silico studies: molecular docking and molecular dynamics simulations.
Main Results:
- Polyphenols exhibited strong binding (10^6 M^-1) and induced conformational changes in the E2 DBD.
- Complexes showed increased thermal stability; binding constants were in the micromolar range.
- Molecular simulations revealed distinct binding sites and stable interactions, with resveratrol binding the helical region and baicalein the dimeric interface.
Conclusions:
- Resveratrol and baicalein are identified as potential candidates for antiviral drug development against HPV 33.
- The findings support targeting the E2 DBD with natural compounds to inhibit viral activity.
